Key facts

Invented name
  • Prevymis
  • Prevymis
Active Substance
Letermovir
Therapeutic area
Infectious diseases
Decision number
P/0362/2019
PIP number
EMEA-001631-PIP01-14-M04
Pharmaceutical form(s)
  • Film-coated tablet
  • Granules
  • Concentrate for solution for infusion
Condition(s) / indication(s)
Prevention of cytomegalovirus infection
Route(s) of administration
  • Oral use
  • Intravenous use
Contact for public enquiries

Merck Sharp & Dohme (Europe), Inc. 

Tel. +33 180464738
E-mail: pip.information@merck.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

P/0362/2019: EMA decision of 4 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for letermovir (Prevymis), (EMEA-001631-PIP01-14-M04)

How useful do you find this page?